CN100347562C - 磁共振研究方法 - Google Patents
磁共振研究方法 Download PDFInfo
- Publication number
- CN100347562C CN100347562C CNB2003101131420A CN200310113142A CN100347562C CN 100347562 C CN100347562 C CN 100347562C CN B2003101131420 A CNB2003101131420 A CN B2003101131420A CN 200310113142 A CN200310113142 A CN 200310113142A CN 100347562 C CN100347562 C CN 100347562C
- Authority
- CN
- China
- Prior art keywords
- reagent
- acid
- polarization
- sample
- nuclear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 107
- 230000005291 magnetic effect Effects 0.000 title claims abstract description 102
- 238000011160 research Methods 0.000 title description 7
- 239000007787 solid Substances 0.000 claims abstract description 55
- 238000003384 imaging method Methods 0.000 claims abstract description 25
- 230000005855 radiation Effects 0.000 claims abstract description 15
- 230000007704 transition Effects 0.000 claims abstract description 13
- 238000009792 diffusion process Methods 0.000 claims abstract description 12
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 230000010412 perfusion Effects 0.000 claims abstract description 4
- 238000011835 investigation Methods 0.000 claims abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 164
- 230000010287 polarization Effects 0.000 claims description 106
- 238000002360 preparation method Methods 0.000 claims description 74
- 230000002102 hyperpolarization Effects 0.000 claims description 50
- 239000000203 mixture Substances 0.000 claims description 35
- 229910052799 carbon Inorganic materials 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 19
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 18
- -1 cinoxazin Chemical compound 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 13
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 12
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 12
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 9
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 9
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 8
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 claims description 8
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 229940107700 pyruvic acid Drugs 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- 239000004202 carbamide Substances 0.000 claims description 5
- 239000001530 fumaric acid Substances 0.000 claims description 5
- 229960002598 fumaric acid Drugs 0.000 claims description 5
- 235000013905 glycine and its sodium salt Nutrition 0.000 claims description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 5
- 229940045136 urea Drugs 0.000 claims description 5
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 claims description 4
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 claims description 4
- DCTLYFZHFGENCW-UUOKFMHZSA-N 5'-xanthylic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 DCTLYFZHFGENCW-UUOKFMHZSA-N 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 claims description 4
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 claims description 4
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 4
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 claims description 4
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims description 4
- ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 claims description 4
- 206010056474 Erythrosis Diseases 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 229960003067 cystine Drugs 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims description 4
- 229960000616 diflunisal Drugs 0.000 claims description 4
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 claims description 4
- 229960002737 fructose Drugs 0.000 claims description 4
- 239000000174 gluconic acid Substances 0.000 claims description 4
- 235000012208 gluconic acid Nutrition 0.000 claims description 4
- 229960002449 glycine Drugs 0.000 claims description 4
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 claims description 4
- 235000013928 guanylic acid Nutrition 0.000 claims description 4
- 239000004226 guanylic acid Substances 0.000 claims description 4
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 4
- 229960000367 inositol Drugs 0.000 claims description 4
- 229960004502 levodopa Drugs 0.000 claims description 4
- 239000002207 metabolite Substances 0.000 claims description 4
- 235000006408 oxalic acid Nutrition 0.000 claims description 4
- 235000008160 pyridoxine Nutrition 0.000 claims description 4
- 239000011677 pyridoxine Substances 0.000 claims description 4
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 4
- 229940034208 thyroxine Drugs 0.000 claims description 4
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims description 4
- 229940116269 uric acid Drugs 0.000 claims description 4
- 229940011671 vitamin b6 Drugs 0.000 claims description 4
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 19
- 230000002503 metabolic effect Effects 0.000 abstract description 4
- 239000000523 sample Substances 0.000 description 52
- 239000007789 gas Substances 0.000 description 36
- 239000000243 solution Substances 0.000 description 30
- 230000008569 process Effects 0.000 description 25
- 239000007788 liquid Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 238000005516 engineering process Methods 0.000 description 18
- 238000002595 magnetic resonance imaging Methods 0.000 description 15
- 239000000126 substance Substances 0.000 description 14
- 239000012071 phase Substances 0.000 description 12
- 229910052805 deuterium Inorganic materials 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 150000003254 radicals Chemical class 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 239000002872 contrast media Substances 0.000 description 9
- 229910052751 metal Inorganic materials 0.000 description 9
- 239000002184 metal Substances 0.000 description 9
- 230000005298 paramagnetic effect Effects 0.000 description 9
- 238000001228 spectrum Methods 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 230000005415 magnetization Effects 0.000 description 8
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 7
- YCKRFDGAMUMZLT-IGMARMGPSA-N Fluorine-19 Chemical compound [19F] YCKRFDGAMUMZLT-IGMARMGPSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000012266 salt solution Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000004435 EPR spectroscopy Methods 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 239000003708 ampul Substances 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052724 xenon Inorganic materials 0.000 description 6
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 6
- 230000005684 electric field Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 239000001307 helium Substances 0.000 description 4
- 229910052734 helium Inorganic materials 0.000 description 4
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- KIPMDPDAFINLIV-UHFFFAOYSA-N 2-nitroethanol Chemical compound OCC[N+]([O-])=O KIPMDPDAFINLIV-UHFFFAOYSA-N 0.000 description 3
- 229910052688 Gadolinium Inorganic materials 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000011261 inert gas Substances 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000005086 pumping Methods 0.000 description 3
- 238000004904 shortening Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101000860173 Myxococcus xanthus C-factor Proteins 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000005388 borosilicate glass Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 238000002144 chemical decomposition reaction Methods 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000005388 cross polarization Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 2
- ZWWCURLKEXEFQT-UHFFFAOYSA-N dinitrogen pentaoxide Chemical compound [O-][N+](=O)O[N+]([O-])=O ZWWCURLKEXEFQT-UHFFFAOYSA-N 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000005283 ground state Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 239000012216 imaging agent Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical group O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002907 paramagnetic material Substances 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000005039 triarylmethyl group Chemical group 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- ZXKXJHAOUFHNAS-FVGYRXGTSA-N (S)-fenfluramine hydrochloride Chemical compound [Cl-].CC[NH2+][C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 ZXKXJHAOUFHNAS-FVGYRXGTSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003262 carboxylic acid ester group Chemical group [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000005274 electronic transitions Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Substances OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000005308 ferrimagnetism Effects 0.000 description 1
- 239000003302 ferromagnetic material Substances 0.000 description 1
- 230000005307 ferromagnetism Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003574 free electron Substances 0.000 description 1
- 239000008246 gaseous mixture Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000000892 gravimetry Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 description 1
- 125000005191 hydroxyalkylamino group Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011810 insulating material Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 150000001455 metallic ions Chemical class 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000005408 paramagnetism Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229930015698 phenylpropene Natural products 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000012887 quadratic function Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000002210 silicon-based material Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000010996 solid-state NMR spectroscopy Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
- A61K49/1815—Suspensions, emulsions, colloids, dispersions compo-inhalant, e.g. breath tests
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/28—Details of apparatus provided for in groups G01R33/44 - G01R33/64
- G01R33/282—Means specially adapted for hyperpolarisation or for hyperpolarised contrast agents, e.g. for the generation of hyperpolarised gases using optical pumping cells, for storing hyperpolarised contrast agents or for the determination of the polarisation of a hyperpolarised contrast agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/62—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using double resonance
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- High Energy & Nuclear Physics (AREA)
- Signal Processing (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- General Induction Heating (AREA)
- Magnetic Ceramics (AREA)
- Control Of Motors That Do Not Use Commutators (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9800158.9 | 1998-01-05 | ||
| GBGB9800158.9A GB9800158D0 (en) | 1998-01-05 | 1998-01-05 | Method |
| GB9813795.3 | 1998-06-25 | ||
| GBGB9813795.3A GB9813795D0 (en) | 1998-06-25 | 1998-06-25 | Method |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB988129531A Division CN1138154C (zh) | 1998-01-05 | 1998-12-23 | 磁共振研究方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1527066A CN1527066A (zh) | 2004-09-08 |
| CN100347562C true CN100347562C (zh) | 2007-11-07 |
Family
ID=26312888
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2003101131420A Expired - Fee Related CN100347562C (zh) | 1998-01-05 | 1998-12-23 | 磁共振研究方法 |
| CNB988129531A Expired - Fee Related CN1138154C (zh) | 1998-01-05 | 1998-12-23 | 磁共振研究方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB988129531A Expired - Fee Related CN1138154C (zh) | 1998-01-05 | 1998-12-23 | 磁共振研究方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6278893B1 (enExample) |
| EP (2) | EP2119457B1 (enExample) |
| JP (1) | JP4764548B2 (enExample) |
| KR (1) | KR100699396B1 (enExample) |
| CN (2) | CN100347562C (enExample) |
| AU (1) | AU752308C (enExample) |
| BR (1) | BRPI9813244B1 (enExample) |
| CA (1) | CA2317526C (enExample) |
| ES (1) | ES2393833T3 (enExample) |
| HU (1) | HU229718B1 (enExample) |
| IL (1) | IL136780A0 (enExample) |
| NO (1) | NO334035B1 (enExample) |
| NZ (1) | NZ505151A (enExample) |
| RU (1) | RU2221255C2 (enExample) |
| WO (1) | WO1999035508A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102782516A (zh) * | 2009-12-30 | 2012-11-14 | 皇家飞利浦电子股份有限公司 | 具有样本传输系统的动态核极化设备 |
Families Citing this family (149)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001503646A (ja) * | 1996-03-29 | 2001-03-21 | ローレンス バークレー ナショナル ラボラトリィ | 過分極化希ガス存在下でのnmrまたはmriの増強 |
| US8765099B2 (en) * | 1996-04-08 | 2014-07-01 | Koninklijke Philips N.V. | Magnetic resonance imaging hyperpolarization of liquids or solids by light with orbital angular momentum |
| EP0951650B1 (en) * | 1997-01-08 | 2003-12-10 | Amersham Health AS | Method of magnetic resonance imaging |
| US6278893B1 (en) * | 1998-01-05 | 2001-08-21 | Nycomed Imaging As | Method of magnetic resonance imaging of a sample with ex vivo polarization of an MR imaging agent |
| NZ508719A (en) | 1998-06-17 | 2002-10-25 | Medi Physics Inc | Hyperpolarized gas transport device with at least one gas chamber and a electromagnet providing a magnetic holding field |
| US6237363B1 (en) * | 1998-09-30 | 2001-05-29 | Medi-Physics, Inc. | Hyperpolarized noble gas extraction methods masking methods and associated transport containers |
| US6284222B1 (en) | 1998-11-03 | 2001-09-04 | Medi--Physics, Inc. | Hyperpolarized helium-3 microbubble gas entrapment methods |
| JP2002534687A (ja) * | 1998-12-30 | 2002-10-15 | アメルシャム・パブリック・リミテッド・カンパニー | 過分極を使用したnmr分光学アッセイ |
| US6566875B1 (en) | 1999-02-23 | 2003-05-20 | Medi-Physics, Inc. | Portable hyperpolarized gas monitoring systems, computer program products, and related methods using NMR and/or MRI during transport |
| US20020058869A1 (en) * | 1999-05-19 | 2002-05-16 | Oskar Axelsson | Methods of magnetic resonance imaging (MRI) using contract agent solutions formed from the dissolution of hyperpolarised materials |
| US6574496B1 (en) * | 1999-05-19 | 2003-06-03 | Amersham Health As | Magnetic resonance imaging |
| US6295834B1 (en) | 1999-06-30 | 2001-10-02 | Medi-Physics, Inc. | NMR polarization monitoring coils, hyperpolarizers with same, and methods for determining the polarization level of accumulated hyperpolarized noble gases during production |
| DE10009166A1 (de) * | 2000-02-26 | 2001-08-30 | Philips Corp Intellectual Pty | Verfahren zur Lokalisierung von Objekten in der interventionellen Radiologie |
| CA2401308A1 (en) | 2000-03-13 | 2001-09-20 | Klaus D. Hagspiel | Diagnostic procedures using direct injection of gaseous hyperpolarized 129xe and associated systems and products |
| GB0009353D0 (en) * | 2000-04-14 | 2000-05-31 | Nycomed Imaging As | Method |
| GB0014463D0 (en) * | 2000-06-14 | 2000-08-09 | Nycomed Amersham Plc | NMR Method |
| US6696040B2 (en) * | 2000-07-13 | 2004-02-24 | Medi-Physics, Inc. | Diagnostic procedures using 129Xe spectroscopy characteristic chemical shift to detect pathology in vivo |
| GB0022341D0 (en) * | 2000-09-12 | 2000-10-25 | Nycomed Imaging As | Method |
| NO20004561D0 (no) * | 2000-09-13 | 2000-09-13 | Nycomed Imaging As | Metode for magnetisk resonansavbildning |
| CN100392422C (zh) | 2000-11-03 | 2008-06-04 | 通用电气医疗集团股份有限公司 | 为nmr分析溶解超极化固体材料的方法和装置 |
| AU1403902A (en) * | 2000-11-03 | 2002-05-15 | Amersham Health As | Methods and devices for polarised nmr samples |
| US7126332B2 (en) * | 2001-07-20 | 2006-10-24 | Baker Hughes Incorporated | Downhole high resolution NMR spectroscopy with polarization enhancement |
| GB0122049D0 (en) * | 2001-09-12 | 2001-10-31 | Nycomed Imaging As | Method |
| RU2281527C2 (ru) * | 2001-11-02 | 2006-08-10 | Амершем Хелт АС | Способ и устройство для плавления поляризованных ямр-образцов |
| NO20023357D0 (no) * | 2002-04-19 | 2002-07-11 | Amersham Health As | Blanding |
| GB0219954D0 (en) * | 2002-08-29 | 2002-10-02 | Amersham Health R & D Ab | Method and apparatus for producing contrast agents for magnetic resonance imaging |
| NO20025124D0 (no) | 2002-10-25 | 2002-10-25 | Amersham Health As | Metode |
| US20060173283A1 (en) * | 2002-11-27 | 2006-08-03 | Oskar Axelsson | Method of magnetic resonance imaging |
| NO20025711D0 (no) * | 2002-11-27 | 2002-11-27 | Amersham Health As | Magnetisk resonansmetode |
| NO20025738D0 (no) | 2002-11-29 | 2002-11-29 | Amersham Health As | Metode |
| DE10259793B4 (de) * | 2002-12-19 | 2009-10-15 | Siemens Ag | Verfahren zur Bildgebung eines Stoffwechselvorgangs eines Lebewesens |
| DE10335663A1 (de) * | 2003-08-04 | 2005-03-10 | Siemens Ag | Verfahren zur automatischen Kalibrierung von Perfusionsparameterbildern |
| NO338547B1 (no) * | 2004-07-30 | 2016-09-05 | Ge Healthcare As | Fremgangsmåte for fremstilling av en flytende sammensetning omfattende hyperpolarisert 13C-pyruvat, sammensetningen og anvendelse av den for fremstilling av hyperpolarisert 13C-pyruvat |
| BRPI0513896A (pt) * | 2004-07-30 | 2008-05-20 | Ge Healthcare As | método para a discriminação entre tecido saudável e de tumor |
| CN101027310B (zh) * | 2004-07-30 | 2012-08-22 | 通用电气医疗集团股份有限公司 | 基团及其在dnp方法中作为顺磁化剂的应用 |
| EP1797102B1 (en) * | 2004-07-30 | 2015-05-27 | Ge Healthcare As | Composition comprising triarylmethyl radical, useful in mri diagnostics |
| US8980224B2 (en) * | 2004-11-19 | 2015-03-17 | Ge Healthcare As | Method of cardiac imaging |
| US7276905B2 (en) * | 2005-07-11 | 2007-10-02 | General Electric Company | Method and system of tracking an intracorporeal device with MR imaging |
| JP2007021008A (ja) | 2005-07-20 | 2007-02-01 | Hitachi Ltd | Dnp過分極手段を備えた磁気共鳴イメージング装置 |
| US20070025918A1 (en) * | 2005-07-28 | 2007-02-01 | General Electric Company | Magnetic resonance imaging (MRI) agents: water soluble carbon-13 enriched fullerene and carbon nanotubes for use with dynamic nuclear polarization |
| US20100259259A1 (en) * | 2005-09-21 | 2010-10-14 | Markus Zahn | Systems and methods for tuning properties of nanoparticles |
| US8377419B2 (en) * | 2005-09-28 | 2013-02-19 | The President And Fellows Of Harvard College | Hyperpolarized solid materials with long spin relaxation times for use as imaging agents in magnetic resonance imaging |
| EP1933884B1 (en) * | 2005-10-11 | 2017-09-06 | Huntington Medical Research Institutes | Imaging agents and methods of use thereof |
| AU2006310100B2 (en) * | 2005-11-06 | 2012-12-06 | Brain Watch Ltd. | Magnetic resonance imaging and spectroscopy means and methods thereof |
| NO20055681D0 (no) * | 2005-12-01 | 2005-12-01 | Amersham Health As | Method of dynamic nuclear polarisation |
| US8951502B2 (en) * | 2005-12-01 | 2015-02-10 | Ge Healthcare As | Method of dynamic nuclear polarisation (DNP) |
| US20080284429A1 (en) * | 2005-12-10 | 2008-11-20 | The President And Fellows Of Harvard College | Situ Hyperpolarization of Imaging Agents |
| JP5102221B2 (ja) * | 2005-12-16 | 2012-12-19 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | 過分極カルボン酸塩の製造方法 |
| JP2009523172A (ja) * | 2006-01-11 | 2009-06-18 | プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ | 造影剤のエクスビボ過分極 |
| US8703102B2 (en) | 2008-04-04 | 2014-04-22 | Millikelvin Technologies Llc | Systems and methods for producing hyperpolarized materials and mixtures thereof |
| AU2013205838B2 (en) * | 2006-02-21 | 2016-03-17 | Avrum Belzer | Hyperpolarization Methods, Systems and Compositions |
| KR101095943B1 (ko) | 2006-02-21 | 2011-12-19 | 밀리켈빈 테크놀로지스 엘엘씨 | 과분극화 방법, 시스템 및 조성물 |
| EP1998813A2 (en) * | 2006-03-29 | 2008-12-10 | GE Healthcare AS | Method to produce hyperpolarised carboxylates and sulphonates in the presence of inorganic cations |
| US7205764B1 (en) * | 2006-04-11 | 2007-04-17 | Varian, Inc. | Method and apparatus for increasing the detection sensitivity in a high resolution NMR analysis |
| MX2008014396A (es) * | 2006-05-11 | 2009-02-06 | Textron Innovations Inc | Dispositivo y metodo para reparar componentes estructurales. |
| EP2018545A4 (en) * | 2006-05-12 | 2011-03-09 | Massachusetts Inst Technology | BIRDICAL POLARIZATION AGENTS FOR DYNAMIC NUCLEAR POLARIZATION APPLICATIONS |
| US20090311189A1 (en) * | 2006-05-12 | 2009-12-17 | Massachusetts Institute Of Technology | Temperature-jump dynamic nuclear polarization |
| US8623327B2 (en) | 2006-06-19 | 2014-01-07 | Beth Israel Deaconess Medical Center, Inc. | Imaging agents for use in magnetic resonance blood flow/perfusion imaging |
| ATE549638T1 (de) * | 2006-08-18 | 2012-03-15 | Ge Healthcare As | 13c-mr-bildgebung oder spektroskopie von zelltod |
| KR101502180B1 (ko) | 2006-08-30 | 2015-03-12 | 지이 헬스케어 에이에스 | 동적 핵 분극화 방법 및 이러한 방법에서 사용되는 화합물 및 조성물 |
| NZ575856A (en) | 2006-10-03 | 2011-06-30 | Univ Duke | Assessing pulmonary gas transfer in lungs using hyperpolarized 129xe mri |
| US7631507B2 (en) | 2006-11-02 | 2009-12-15 | General Electric Company | Methods and devices for polarized samples for use in MRI |
| US8849372B2 (en) * | 2006-11-22 | 2014-09-30 | The General Hospital Corporation | Method for magnetic resonance imaging using stimulus induced rotary saturation with a contrast agent |
| WO2008072142A1 (en) * | 2006-12-11 | 2008-06-19 | Koninklijke Philips Electronics N.V. | Fibre tracking on the basis of macroscopic information |
| EP2117607A4 (en) * | 2007-01-11 | 2012-08-08 | Huntington Medical Res Inst | PICTURES AND METHOD FOR THEIR USE |
| US20080240998A1 (en) | 2007-03-28 | 2008-10-02 | Urbahn John A | Fluid path system for dissolution and transport of a hyperpolarized material |
| US20080275668A1 (en) * | 2007-05-02 | 2008-11-06 | General Electric Company | Apparatus and method for fully automated closed system optical measurement of volume |
| US7610157B2 (en) * | 2007-05-02 | 2009-10-27 | General Electric Company | Apparatus and method for fully automated closed system pH measurement |
| US7519492B2 (en) * | 2007-05-02 | 2009-04-14 | General Electric Company | Apparatus and method for fully automated closed system quality control of a substance |
| US7741844B2 (en) | 2007-05-07 | 2010-06-22 | General Electric Company | Method and system for magnetic resonance imaging using labeled contrast agents |
| US9042978B2 (en) * | 2007-05-11 | 2015-05-26 | Neurometrix, Inc. | Method and apparatus for quantitative nerve localization |
| GB2450316A (en) * | 2007-06-18 | 2008-12-24 | Univ York | Hyperpolarizing nuclei |
| DE102007028901B4 (de) * | 2007-06-22 | 2010-07-22 | Siemens Ag | Verfahren und Vorrichtung zur automatischen Bestimmung von Perfusion mittels einer Magnetresonanzanlage |
| US20080314836A1 (en) * | 2007-06-22 | 2008-12-25 | General Electric Company | Methods and devices for dynamic filtration of pharmaceutical products |
| US9227173B2 (en) | 2007-06-22 | 2016-01-05 | General Electric Company | Methods for dynamic filtration of pharmaceutical products |
| GB0713074D0 (en) * | 2007-07-05 | 2007-08-15 | Univ London | A method of hyperpolarising a magnetic resonance agent |
| ATE534408T1 (de) * | 2007-08-27 | 2011-12-15 | Ge Healthcare Ltd | Bildgebungsmedium mit hyperpolarisiertem uüc- acetat und seine verwendung |
| US20100233089A1 (en) * | 2007-10-05 | 2010-09-16 | Huntington Medical Research Institutes | Imaging of genetic material with magnetic resonance |
| EP2902041A1 (en) | 2007-12-19 | 2015-08-05 | GE Healthcare Limited | Composition and method for generating a metabolic profile using 13C-MR detection |
| CN101971011B (zh) * | 2007-12-20 | 2014-03-26 | 皇家飞利浦电子股份有限公司 | 利用通过具有轨道角动量的光超极化液体或固体的磁共振成像 |
| JP4871311B2 (ja) * | 2008-02-26 | 2012-02-08 | 株式会社日立製作所 | 核磁気共鳴装置、磁気共鳴イメージング装置および磁気共鳴分析装置 |
| GB0804422D0 (en) * | 2008-03-10 | 2008-04-16 | Univ Southampton | An agent for transporting nuclear spin order and for magnetic resonance imaging |
| US20140223923A1 (en) * | 2008-04-04 | 2014-08-14 | Millikelvin Technologies Llc | Systems and methods for producing hyperpolarized materials and mixtures thereof |
| WO2009129265A1 (en) * | 2008-04-14 | 2009-10-22 | Huntington Medical Research Institutes | Methods and apparatus for pasadena hyperpolarization |
| US8763410B2 (en) | 2008-04-21 | 2014-07-01 | General Electric Company | Method and apparatus for the dissolution and filtration of a hyperpolarized agent with a neutral dissolution media |
| EP2268321B1 (en) | 2008-05-02 | 2013-10-09 | General Electric Company | Method of determining alanine transaminase (ALT) activity by 13C-MR detection using hyperpolarised 13C-pyruvate |
| US9658300B1 (en) * | 2008-08-19 | 2017-05-23 | California Institute Of Technology | Method and apparatus for preparation of spin polarized reagents |
| US9289518B2 (en) * | 2008-08-22 | 2016-03-22 | The Brigham And Women's Hospital | Enhanced 13C NMR by thermal mixing with hyperpolarized 129XE |
| US7633290B1 (en) | 2008-09-09 | 2009-12-15 | General Electric Company | Apparatus and method for a fully automated preparation of a hyperpolarizing imaging agent |
| US20100092390A1 (en) * | 2008-10-09 | 2010-04-15 | President And Fellows Of Harvard College | Methods for Making Particles Having Long Spin-Lattice Relaxation Times |
| US20110274626A1 (en) | 2008-12-10 | 2011-11-10 | University Of York | Pulse sequencing with hyperpolarisable nuclei |
| RU2543704C2 (ru) | 2009-04-02 | 2015-03-10 | ДжиИ ХЕЛТКЕР ЛИМИТЕД | Применение магнитно-резонансной визуализирующей среды, содержащей гиперполяризованный 13с-пируват, для обнаружения воспаления или инфекции |
| RU2531129C2 (ru) * | 2009-06-19 | 2014-10-20 | Конинклейке Филипс Электроникс Н.В. | Термометрия mri, объединенная с устройством гиперполяризации, использующим фотоны с орбитальным угловым моментом |
| EP2473199A1 (en) | 2009-08-31 | 2012-07-11 | Brain Watch Ltd. | Isotopically labeled neurochemical agents and uses thereof for diagnosing conditions and disorders |
| CA2772190A1 (en) | 2009-08-31 | 2011-03-03 | Millikelvin Technologies Llc | Systems and methods for producing hyperpolarized materials and mixtures thereof |
| US8968703B2 (en) | 2009-09-10 | 2015-03-03 | Ge Healthcare Limited | 13C-MR detection using hyperpolarised 13C-fructose |
| US8427161B2 (en) * | 2009-12-18 | 2013-04-23 | General Electric Company | Method and apparatus for generating hyperpolarized materials |
| RU2565337C2 (ru) * | 2010-02-16 | 2015-10-20 | Конинклейке Филипс Электроникс Н.В. | Оптическая гиперполяризация на основе света, обладающего оптическим угловым моментом |
| EP2555803B1 (en) | 2010-04-08 | 2018-09-12 | Bracco Imaging S.p.A | Process for preparing hyperpolarized substrates and method for mri |
| US8970217B1 (en) | 2010-04-14 | 2015-03-03 | Hypres, Inc. | System and method for noise reduction in magnetic resonance imaging |
| KR101858269B1 (ko) | 2010-05-03 | 2018-05-15 | 지이 헬쓰케어 리미티드 | 락테이트 탈수소효소 활성의 측정을 위한 과분극화된 락테이트 조영제 |
| DE102010017568B4 (de) | 2010-06-24 | 2012-09-13 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Hyperpolarisationseinrichtung und Verfahren zur Verabreichung eines hyperpolarisierten flüssigen Kontrastmittels |
| WO2012056447A1 (en) | 2010-10-25 | 2012-05-03 | Brain Watch Ltd. | Isotopically labeled deoxy-glucose and derivatives thereof, compositions comprising them and uses thereof |
| US8786284B2 (en) * | 2011-01-11 | 2014-07-22 | Bridge12 Technologies, Inc. | Integrated high-frequency generator system utilizing the magnetic field of the target application |
| MX2013010754A (es) * | 2011-03-23 | 2014-03-26 | Millikelvin Technologies Llc | Tecnicas, sistemas y programas legibles por maquina mejorados para resonancia magnetica. |
| US20140099262A1 (en) | 2011-06-01 | 2014-04-10 | Brain Watch Ltd. | Isotopically labeled cdp-choline and uses thereof |
| US9511154B2 (en) | 2011-10-12 | 2016-12-06 | Bracco Imaging S.P.A. | Process for the preparation of hyperpolarized derivatives for use in MRI analysis |
| EP2788035B1 (en) | 2011-12-05 | 2016-03-09 | Bracco Imaging S.p.A | Composition comprising acetic anhydride and a gadolinium complex, and method for the use in hyperpolarisation mri analysis |
| GB2498181A (en) | 2011-12-29 | 2013-07-10 | Bruker Biospin Gmbh | Device and method for rapid dynamic nuclear polarisation |
| IL223935A (en) | 2012-01-13 | 2016-11-30 | Gen Electric | Fluid track system for decomposition and transport of hyper-polarized material |
| EP2624004A1 (en) * | 2012-02-06 | 2013-08-07 | Koninklijke Philips Electronics N.V. | Temperature determination using magnetic resonance B1 field mapping |
| US8715621B2 (en) | 2012-03-15 | 2014-05-06 | Massachusetts Institute Of Technology | Radical polarizing agents for dynamic nuclear polarization |
| EP2642310A1 (en) | 2012-03-22 | 2013-09-25 | Koninklijke Philips N.V. | Interpolated three-dimensional thermal dose estimates using magnetic resonance imaging |
| WO2013149935A1 (en) | 2012-04-02 | 2013-10-10 | Bracco Imaging Spa | Hyperpolarized amino acids |
| US9329245B2 (en) * | 2012-04-11 | 2016-05-03 | Bruker Biospin Ag | MRI compatible method and device for rapid DNP on a solid state hyperpolarized sample material |
| EP2847591A1 (en) | 2012-05-07 | 2015-03-18 | Albeda Innovation ApS | Intra-operative cancer diagnosis based on a hyperpolarized marker |
| US8825132B2 (en) | 2012-07-04 | 2014-09-02 | Bruker Biospin Gmbh | Field cycling method for magnetic resonance |
| US9381257B2 (en) | 2012-07-13 | 2016-07-05 | Bracco Imaging S.P.A. | Triarylmethyl radicals |
| US9329246B2 (en) | 2012-10-03 | 2016-05-03 | Bruker Biospin Ag | Method for hyperpolarization transfer in the liquid state |
| US20150273086A1 (en) | 2012-10-25 | 2015-10-01 | Bracco Imaging S.P.A. | Hyperpolarized 2-oxoglutarate as metabolic agent in mr |
| US9404984B2 (en) | 2012-11-06 | 2016-08-02 | Bruker Uk Limited | Method of hyperpolarization applying brute force using particulate acceleration agents |
| US20140200437A1 (en) * | 2013-01-16 | 2014-07-17 | Empire Technology Development Llc | Detection of internal gas leakage |
| KR102255333B1 (ko) | 2013-01-31 | 2021-05-26 | 브라코 이미징 에스.피.에이. | Mr에서 대사 마커로서 사용되는 과분극화된 에스테르 |
| EP3016687B1 (en) * | 2013-07-01 | 2017-08-09 | Bracco Imaging S.p.A | Hyperpolarized 1-13c-1,1-bis(acetoxy(methyl))-2,2'-cyclopropane as metabolic marker for mr |
| US9642924B2 (en) * | 2013-08-29 | 2017-05-09 | Duke University | Contrast agents based on long-lived nuclear singlet states and related methods |
| US9874622B2 (en) | 2013-09-27 | 2018-01-23 | General Electric Company | Hyperpolarized media transport vessel |
| EP2863229A1 (en) | 2013-10-15 | 2015-04-22 | Technische Universität München | pH-biosensors based on compounds with pH-sensitive enolic groups for magnetic resonance imaging and spectroscopy and their uses |
| EP2891500B1 (en) | 2014-01-07 | 2018-08-01 | Cambridge Enterprise Limited | Contrast agent for determination of aldehyde dehydrogenase (ALDH) activity |
| EP3015855A1 (en) | 2014-10-27 | 2016-05-04 | Klinikum rechts der Isar der Technischen Universität München | Metal biosensors based on compounds with metal-sensitive chemical shifts for magnetic resonance spectroscopy and imaging |
| US10088536B2 (en) * | 2015-03-27 | 2018-10-02 | Bruker Biospin Corporation | Sample introduction system and method for polarization |
| US10649044B2 (en) * | 2015-05-22 | 2020-05-12 | Universität Ulm | Method for the hyperpolarisation of nuclear spins |
| JP6491747B2 (ja) * | 2015-09-30 | 2019-03-27 | デューク・ユニヴァーシティ | 磁気共鳴画像法用の造影剤 |
| CN105738397B (zh) * | 2016-02-04 | 2017-09-29 | 浙江大学 | 化合物中季碳纵向驰豫时间(t1)的分析方法 |
| CN105866158B (zh) * | 2016-03-31 | 2017-12-15 | 武汉大学 | 基于磁共振耦合的无损溶液浓度检测装置及检测方法 |
| EP3258285B1 (en) * | 2016-06-14 | 2020-10-21 | Bruker BioSpin GmbH | Method for predicting chemical shift values of nmr spin systems in a sample of a fluid class, in particular in a sample of a biofluid |
| US10390727B2 (en) * | 2017-04-21 | 2019-08-27 | The Charles Stark Draper Laboratory, Inc. | Apparatus and method for imaging currents using nanoparticles and low-field magnetic resonance imaging (MRI) |
| GB201710677D0 (en) * | 2017-07-03 | 2017-08-16 | Univ York | Polorisation transfer via a second metal complex |
| US11330999B2 (en) * | 2017-09-12 | 2022-05-17 | Memorial Sloan Kettering Cancer Center | Hyperpolarized and deuterium exchanged hyperpolarized13C and 15N-labeled xanthine, arginine, glutamine, and urea probes |
| US10520561B2 (en) | 2017-09-27 | 2019-12-31 | General Electric Company | System and method for hyperpolarizing a substance and quenching radicals therein |
| WO2019145955A1 (en) * | 2018-01-26 | 2019-08-01 | Hadasit Medical Research Services & Development Limited | Non-metallic magnetic resonance contrast agent |
| US10942237B2 (en) | 2019-05-07 | 2021-03-09 | GE Precision Healthcare LLC | System and method for hyperpolarizing a substance |
| US11428763B2 (en) * | 2020-02-28 | 2022-08-30 | Government Of The United States Of America, As Represented By The Secretary Of Commerce | Planar inverse anapole microresonator and performing inductive-detection electron paramagnetic resonance spectroscopy |
| US11940510B2 (en) * | 2020-03-31 | 2024-03-26 | Nvision Imaging Technologies Gmbh | Systems and method for generation of hyperpolarized materials |
| CN112268918A (zh) * | 2020-07-10 | 2021-01-26 | 中国科学院过程工程研究所 | 一种基于固体核磁共振波谱仪的材料吸附气体原位分析装置 |
| US20230302161A1 (en) * | 2020-08-25 | 2023-09-28 | Biographene Inc. | Mri contrast medium including carbon-13-containing graphene quantum dot and preparation method therefor |
| CN114690099B (zh) * | 2020-12-30 | 2025-05-06 | 中国科学技术大学 | 光超极化核磁共振成像装置及方法 |
| US12409239B2 (en) * | 2021-06-25 | 2025-09-09 | Beacon Mri Ltd | Particles for use in hyperpolarization |
| GB202111734D0 (en) | 2021-08-16 | 2021-09-29 | Cambridge Entpr Ltd | Hyperpolarisation method and product |
| WO2024191654A1 (en) * | 2023-03-10 | 2024-09-19 | North Carolina State University | Magnetic field control of sabre hyperpolarized molecules for processing and administration |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1121314A (zh) * | 1993-03-16 | 1996-04-24 | 奈科姆成像有限公司 | 造影剂或与其相关的改进 |
| US5617859A (en) * | 1995-10-02 | 1997-04-08 | General Electric Company | Apparatus and methods for magnetic resonance (MR) imaging of cavities using fluids polarized at low temperatures |
| CN1076205C (zh) * | 1992-08-13 | 2001-12-19 | 勃勒柯国际有限公司 | 用于核磁共振成像的颗粒及其制备方法 |
| CN1138154C (zh) * | 1998-01-05 | 2004-02-11 | 耐克麦德英梅金公司 | 磁共振研究方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2058714T3 (es) | 1987-06-23 | 1994-11-01 | Nycomed Innovation Ab | Mejoras introducidas en formacion de imagenes por resonancia magnetica. |
| GB8817137D0 (en) | 1988-07-19 | 1988-08-24 | Nycomed As | Compositions |
| GB8819753D0 (en) * | 1988-08-19 | 1988-09-21 | Nycomed As | Apparatus |
| JPH02111747A (ja) * | 1988-10-21 | 1990-04-24 | Nippon Steel Chem Co Ltd | 炭素13標識5‐アミノレブリン酸及びその誘導体の製造方法 |
| JP3166160B2 (ja) * | 1989-02-15 | 2001-05-14 | 味の素株式会社 | 新規な▲上1▼▲上3▼c標識アミノ酸及びその発酵的又は酵素的製造法 |
| FI923589L (fi) | 1990-02-12 | 1992-08-11 | Hafslund Nycomed Innovation | Triarylmetylradikaler och anvaendning av inerta fria kolradikaler i mri. |
| US5413917A (en) * | 1990-07-18 | 1995-05-09 | Board Of Regents, The University Of Texas System | Method of determining sources of acetyl-CoA under nonsteady-state conditions |
| AU668691B2 (en) | 1991-08-09 | 1996-05-16 | Nycomed Innovation Ab | Use of persistent free-radicals in magnetic resonance imaging |
| JPH0597711A (ja) * | 1991-10-04 | 1993-04-20 | 節 ▲築▼山 | 生体組織代謝検査法 |
| RU2063702C1 (ru) * | 1992-07-20 | 1996-07-20 | Леонид Аврамович Тютин | Способ магнитно-резонансной томографии и устройство для его осуществления |
| US5545396A (en) | 1994-04-08 | 1996-08-13 | The Research Foundation Of State University Of New York | Magnetic resonance imaging using hyperpolarized noble gases |
| US5479925A (en) | 1994-06-23 | 1996-01-02 | General Electric Company | Magnetic resonance (MR) angiography in a low-field imaging magnet |
| GB9419203D0 (en) | 1994-09-23 | 1994-11-09 | Nycomed Innovation Ab | Contrast media |
| JP3897841B2 (ja) * | 1995-10-31 | 2007-03-28 | 独立行政法人科学技術振興機構 | 標識アシル−l−カルニチンを用いた疾患診断剤 |
| JP2001503646A (ja) | 1996-03-29 | 2001-03-21 | ローレンス バークレー ナショナル ラボラトリィ | 過分極化希ガス存在下でのnmrまたはmriの増強 |
| GB9614139D0 (en) | 1996-07-05 | 1996-09-04 | Nycomed Imaging As | Method |
| EP0951650B1 (en) | 1997-01-08 | 2003-12-10 | Amersham Health AS | Method of magnetic resonance imaging |
| US6125654A (en) | 1998-10-16 | 2000-10-03 | Syracuse University | Bulk production and usage of hyperpolarized 129 Xenon |
| FR2833953B1 (fr) | 2001-12-21 | 2004-12-03 | Sanofi Synthelabo | DERIVES DE 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO [4,5-b]INDOLE-1-CARBOXAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
-
1998
- 1998-10-09 US US09/169,148 patent/US6278893B1/en not_active Expired - Lifetime
- 1998-12-23 IL IL13678098A patent/IL136780A0/xx not_active IP Right Cessation
- 1998-12-23 WO PCT/GB1998/003904 patent/WO1999035508A1/en not_active Ceased
- 1998-12-23 JP JP2000527838A patent/JP4764548B2/ja not_active Expired - Fee Related
- 1998-12-23 EP EP09009608A patent/EP2119457B1/en not_active Expired - Lifetime
- 1998-12-23 KR KR1020007007423A patent/KR100699396B1/ko not_active Expired - Fee Related
- 1998-12-23 RU RU2000120670/09A patent/RU2221255C2/ru not_active IP Right Cessation
- 1998-12-23 CN CNB2003101131420A patent/CN100347562C/zh not_active Expired - Fee Related
- 1998-12-23 ES ES09009608T patent/ES2393833T3/es not_active Expired - Lifetime
- 1998-12-23 CN CNB988129531A patent/CN1138154C/zh not_active Expired - Fee Related
- 1998-12-23 AU AU17753/99A patent/AU752308C/en not_active Ceased
- 1998-12-23 CA CA002317526A patent/CA2317526C/en not_active Expired - Fee Related
- 1998-12-23 HU HU0102093A patent/HU229718B1/hu not_active IP Right Cessation
- 1998-12-23 BR BRPI9813244A patent/BRPI9813244B1/pt not_active IP Right Cessation
- 1998-12-23 NZ NZ505151A patent/NZ505151A/xx not_active IP Right Cessation
- 1998-12-23 EP EP98962629A patent/EP1046051A1/en not_active Withdrawn
-
2000
- 2000-06-22 NO NO20003251A patent/NO334035B1/no not_active IP Right Cessation
- 2000-06-30 US US09/609,153 patent/US6466814B1/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1076205C (zh) * | 1992-08-13 | 2001-12-19 | 勃勒柯国际有限公司 | 用于核磁共振成像的颗粒及其制备方法 |
| CN1121314A (zh) * | 1993-03-16 | 1996-04-24 | 奈科姆成像有限公司 | 造影剂或与其相关的改进 |
| US5617859A (en) * | 1995-10-02 | 1997-04-08 | General Electric Company | Apparatus and methods for magnetic resonance (MR) imaging of cavities using fluids polarized at low temperatures |
| CN1138154C (zh) * | 1998-01-05 | 2004-02-11 | 耐克麦德英梅金公司 | 磁共振研究方法 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102782516A (zh) * | 2009-12-30 | 2012-11-14 | 皇家飞利浦电子股份有限公司 | 具有样本传输系统的动态核极化设备 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1285044A (zh) | 2001-02-21 |
| EP1046051A1 (en) | 2000-10-25 |
| AU1775399A (en) | 1999-07-26 |
| HUP0102093A3 (en) | 2004-09-28 |
| NO20003251L (no) | 2000-06-22 |
| JP4764548B2 (ja) | 2011-09-07 |
| RU2221255C2 (ru) | 2004-01-10 |
| NO334035B1 (no) | 2013-11-25 |
| KR100699396B1 (ko) | 2007-03-27 |
| CN1138154C (zh) | 2004-02-11 |
| NO20003251D0 (no) | 2000-06-22 |
| NZ505151A (en) | 2002-11-26 |
| CA2317526A1 (en) | 1999-07-15 |
| CA2317526C (en) | 2008-09-16 |
| BR9813244A (pt) | 2000-10-10 |
| AU752308C (en) | 2003-05-15 |
| HK1069635A1 (zh) | 2005-05-27 |
| ES2393833T3 (es) | 2012-12-28 |
| BRPI9813244B1 (pt) | 2016-12-13 |
| HUP0102093A2 (hu) | 2001-09-28 |
| US6466814B1 (en) | 2002-10-15 |
| EP2119457B1 (en) | 2012-10-03 |
| US6278893B1 (en) | 2001-08-21 |
| KR20010040318A (ko) | 2001-05-15 |
| AU752308B2 (en) | 2002-09-12 |
| EP2119457A1 (en) | 2009-11-18 |
| JP2002501006A (ja) | 2002-01-15 |
| IL136780A0 (en) | 2001-06-14 |
| CN1527066A (zh) | 2004-09-08 |
| HU229718B1 (hu) | 2014-05-28 |
| WO1999035508A1 (en) | 1999-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100347562C (zh) | 磁共振研究方法 | |
| Pinon et al. | Hyperpolarization via dissolution dynamic nuclear polarization: new technological and methodological advances | |
| US20020058869A1 (en) | Methods of magnetic resonance imaging (MRI) using contract agent solutions formed from the dissolution of hyperpolarised materials | |
| KR100834255B1 (ko) | 핵 스핀 편극화 mr 영상화제를 사용한 샘플의 자기 공명연구 방법 | |
| CN101970014A (zh) | 包含超极化的13c-乳酸盐的成像介质及其用途 | |
| Kwiatkowski et al. | Direct hyperpolarization of micro-and nanodiamonds for bioimaging applications–considerations on particle size, functionalization and polarization loss | |
| US8003077B2 (en) | Method for the production of hyperpolarized 129Xe | |
| WO2000072031A1 (en) | Methods of magnetic resonance imaging (mri) using contract agent solutions formed from the dissolution of hyperpolarised materials | |
| HK1069635B (en) | Method of magnetic resonance investigation | |
| Parish et al. | Dynamic nuclear polarization of carbonyl and methyl 13C spins of acetate using 4-oxo-TEMPO free radical | |
| AU2003274845B2 (en) | Method for the production of hyperpolarized 129Xe | |
| Capozzi et al. | Photo-Induced non-Persistent Radicals as Polarizing Agents for X-Nuclei Dissolution-DNP | |
| Ardenkjaer-Larsen et al. | Hyperpolarization via dissolution Dynamic Nuclear Polarization: new technological and methodological advances |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1069635 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1069635 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071107 Termination date: 20171223 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |